Item request has been placed!
×
Item request cannot be made.
×

Processing Request
Item request has been placed!
×
Item request cannot be made.
×

Processing Request
-
Source:
A Phase II Study of Pembrolizumab Plus Platinum and Pemetrexed as First Line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer Patients With EGFR Exon 21 Point
تفاصيل العنوان
-
Authors :
Thomas Sciascia, MD/Chief Medical Officer and VP Clinical Operations and Regulatory Affairs
-
Source:
A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 Day, Two-arm, Parallel Group Study of A0001 in Patients With the A3243G Mitochondrial DNA Point
تفاصيل العنوان
-
Authors :
Kim Ji Hyun, Clinical Professor
-
Source:
Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A
تفاصيل العنوان
-
Authors :
Anna Woodbury, Associate Professor
-
Source:
Trans-auricular Nerve Stimulation as an Innovative Approach to the Treatment of Pain in Pediatric Patients Suffering From Sickle Cell Disease
تفاصيل العنوان
-
Source:
A Phase 2a Safety, Tolerability, and Pharmacodynamic Study of OMT-28 in PMD Patients With Myopathy and/or Cardiomyopathy and Inflammation (PMD-OPTION)
تفاصيل العنوان
-
Source:
Evaluation of the Diagnostic Performance of Non-Invasive Prenatal Diagnosis for Single Gene DisordersPacault M, Verebi C, Champion M, Orhant L, Perrier A, Girodon E, Leturcq F, Vidaud D, Ferec
تفاصيل العنوان
-
Source:
Prevalence, Kinetic and Prognostic Value of XPO1 E571K Mutation Detection in Plasma Cell-free DNA From Patients Xith Classical Hodgkin LymphomaCamus V, Viennot M,
تفاصيل العنوان
-
Source:
Population-based New-Born Screening of Spinal Muscular Atrophy to Evaluate the Uptake and Feasibility in the UK Context
تفاصيل العنوان
-
Source:
A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth
تفاصيل العنوان